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INTRODUCTION 
Spasticity is a symptom often found in neuromuscular diseases 
such as Cerebral Palsy (CP). Spasticity is characterised by 
involuntary muscular contractions caused by lesions in the 
brain developed at or just after birth [1]. Spasticity, over time, 
causes increased passive stiffness and hypoextensibility [2]. A 
current treatment to provide temporary relief from spasticity is 
the application of botulinum toxin type-A (BTXA) injections. 
BTXA is a neurotoxin that prevents the release of 
acetylcholine at neuromuscular junctions, therefore relaxing 
the muscle [3]. Recent literature suggests that BTXA 
decreases passive stiffness by changing skeletal muscle 
structural components [3]. These include changes to 
connective tissue such as collagen structure, contractile 
proteins such as myosin, as well as structural proteins such as 
titin [3]. Unfortunately, there is limited information regarding 
these changes to skeletal muscle structural components caused 
by BTXA despite being used clinically [3]. There is limited 
literature of the effects of short term BTXA on passive 
mechanics in skeletal muscle [3]. Therefore, the purpose of 
this experiment was to obtain a deeper understanding of the 
effects of BTXA injections on skeletal muscle properties first 
in passive mechanic changes and secondly through structural 
changes during an acute 5 day protocol.  
METHODS 
A New Zealand white rabbit animal model (n=4) was used.  
One hind limb acted as the experimental leg and the 
contralateral leg acted as the control. A pre- and post-test for 
passive force was performed using a minimally traumatic pin 
and motor system, once before a BTXA injection (3.5u/kg) 
and once 5 days after injection. Each test consisted of 5 trials, 
each with 3 movements (25°/sec). The BTXA was divided into 
4 doses and injected intramuscularly into 4 quadrants of the 
lower limb plantar flexors (proximal medial, proximal lateral, 
distal medial and distal lateral) of the experimental limb. 
When the post-test was completed the rabbits were euthanized 
and the hind limbs extracted for future tissue work.   
RESULTS 
Two rabbits showed a trend of decreasing passive force after 
BTXA, like the example showed in Figure 1, and two rabbits 
showed a trend of increasing passive force after BTXA.  No 
changes from the pre- to post- test results were statistically 
significant. There was also no statistical difference in passive 
forces when all four were considered. 
 
Figure 1. Passive torque vs. ankle joint graph for one rabbit 
showing a decrease in passive force from pre-test to post-test 
recording. A paired sample t-test determined that there was no 
difference in passive force between pre- and post-test 
measurements across all animals.  
DISCUSSION AND CONCLUSIONS 
Our results show that BTXA does not change passive force. If 
these results are accurate, despite being an effective tool in 
preventing spasticity, BTXA would need to be supplemented 
with other treatments to improve on stiffness and 
hypoextensibility in CP patients. However previous literature 
suggests that passive force decreases with the injection of 
BTXA [3], therefore possibilities why this did not occur may 
be due to: the amount of BTXA injected, the number of 
rabbits, and the sensitivity of our equipment. In the future we 
will continue to test changes in passive force using two 
additional rabbits to increase the sample size, as well as use 
the extracted tissue from each rabbit to run titin isoform tests, 
collagen content tests, and sarcomere count tests to observe if 
BTXA caused changes in the skeletal muscle structure itself.  
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